Gadalquiver, John .
HRN: 21-47-96 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/26/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
06/26/2022
07/02/2022
IV
500 Mg
Q6H
Intestinal Amoebiasis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Non-compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes